Company working aggressively to regain compliance Common stock to continue to trade on NYSE American during the appeal process CRANBURY, N.J., April 14, 2025 /PRNewswire/ -- Palatin Technologies, Inc. (the "Company") (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, announced today that it has formally appealed the NYSE Regulation determination to delist its common stock. NYSE R

NEW YORK, April 14, 2025 /PRNewswire/ -- Medication non-adherence is a significant and preventable challenge in healthcare, contributing to an estimated 15% of all healthcare spending, or up to $300 billion annually. Patients skipping doses or abandoning treatments don't just face worse health outcomes — they drive avoidable hospitalizations, complications, and increased costs for the healthcare ecosystem. Sidekick Health is tackling this problem head-on with an innovative, integrated approach

COLUMBUS, Ga., April 14, 2025 /PRNewswire/ -- hyperCORE International is pleased to welcome Atlas Clinical Research, based in Durham, North Carolina, to its partner site network, as the clinical research organization continues to expand its global reach and capabilities through alliance partnerships. Continue Reading Atlas Clinical Research is a therapeutically driven clinical research site network built on centralized process excellence and integrated technology. Atlas sites and physicians form

SAN DIEGO, April 14, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, today announced that its executive team will be available for 1x1 meetings at the Piper Sandler Spring Biopharma Symposium on April 17th in Boston, MA. About Skye Bioscience Skye is focused on unlocking new therapeutic pathways for metabolic health through the de

Board of Directors has approved plan to liquidate and intends to seek stockholder approval for dissolution of the Company at the Annual Meeting of Stockholders on June 5, 2025 Initial distribution expected in the range between approximately $246.6 million and $255.4 million, or approximately $5.13 and $5.33 per share of common stock, expected in the third quarter of 2025 Sale of the Company’s assets, including THB335, to be initiated pending stockholder approval of the Plan of Liquidation

Targeting to initiate Phase 3 randomized registrational trial for darovasertib in the neoadjuvant setting in primary UM in H1 2025 Clinical endpoints supportive of full approval based on FDA Type D Meeting: Eye preservation rate as the primary endpoint for enucleation patients. Proportion of patients with best corrected visual acuity 15-letter loss from time of randomization and time of completion of plaque brachytherapy (PB) as the primary endpoint for PB patients. No detriment to Event-Free-Su

EDINBURGH, Scotland, April 14, 2025 /PRNewswire/ -- Chromatin Bioscience, a leader in the design of synthetic promoters and gene control systems, is pleased to announce a collaboration agreement with Astellas Pharma, a global life sciences company. Under the agreement, Chromatin Bioscience will use its proprietary chromatinLENS platform to design cell-selective synthetic promoters aligned with Astellas' target profile. The designed promoters are expected to enable highly precise and durable ge

BASEL, Switzerland I April 14, 2025 I Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Commission has approved Columvi® (glofitamab) in combination with gemcitabine and oxaliplatin (GemOx) for the treatment of adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) not otherwise specified who are ineligible for autologous stem cell transplant (ASCT). With this approval, this Columvi combination is the first bispecific antibody regimen available

Strategic Partnership Aims to Create Novel Drug Discovery Pipeline for Unmet Medical Needs by Combining PPI Control Technology with AI Drug Discovery Platform TOKYO, April 14, 2025 /PRNewswire/ -- PRISM BioLab, Co. Ltd. ("PRISM BioLab"), a leading discovery and development biotechnology company designing small molecule inhibitors of protein-protein interaction (PPI) targets, today announced that it has entered into a drug discovery collaboration with Elix, Inc. ("Elix"), effective April 1, 2025.

Verve Therapeutics is trying to swerve the gene editing industry downturn with new results on a potential one-time treatment to lower cholesterol. The experimental gene editing therapy cut bad cholesterol by levels comparable to approved heart disease treatments in an early-stage study. VERVE-102 is designed to edit the gene for PCSK9, a protein that’s key in regulating cholesterol, and is Verve’s second clinical program targeting that gene. In 14 patients studied so far, Verve has not seen the